dc.contributor.author |
Jyotsna Nambiar |
|
dc.contributor.author |
Geetha, B K |
|
dc.contributor.author |
Sanjana, S R |
|
dc.contributor.author |
Gorantla, J N |
|
dc.contributor.author |
Ravi S Lankalapalli |
|
dc.contributor.author |
Bipin G Nair |
|
dc.date.accessioned |
2016-06-02T06:02:10Z |
|
dc.date.available |
2016-06-02T06:02:10Z |
|
dc.date.issued |
2015-04-15 |
|
dc.identifier.citation |
International Journal of Pharma and Bio Sciences 6(2):(B)1435-1444,15-Apr,2015 |
en_US |
dc.identifier.uri |
http://hdl.handle.net/123456789/2309 |
|
dc.description.abstract |
Aberrant expression of Matrix Metalloproteinases (MMPs) has been correlated with a
wide range of diseases including several forms of cancers. MMPs are implicated in
tumor cell invasion and metastasis as well as abnormalities of oncogenicsignalling
cascades like the Epidermal Growth Factor (EGF) pathway. We have recently reported
the synthesis of 3,5-dihydroxypyridine derivativesvia 2-pyridone produced in an unusual
aromatization of a lactam intermediate derived from D-galactose. The present study
demonstrates for the first time, that one such pyridone derivative, 3, 5-
dihydroxypyridinewith a C2 substituted tetradecyloxy chain (TD-2), showed inhibition of
gelatinases, both at the level of activity and RNA expression without affecting the
viability of the fibrosarcoma cell line HT1080. Further, TD-2 was also shown to inhibit
Akt, one of the major components of the oncogenic EGF cascade. These studies
provide evidence for a novel TD-2 mediated regulation of MMPs and the EGF pathway |
en_US |
dc.language.iso |
en |
en_US |
dc.publisher |
ijpbs |
en_US |
dc.subject |
Matrix metalloproteinases;3,5-dihydroxypyridine;fibrosarcoma;epidermal growth factor;Akt |
en_US |
dc.title |
A novel2-alkoxy-3, 5-dihydroxypyridine mediated regulation of gelatinases |
en_US |
dc.type |
Article |
en_US |